Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.06
(-0.49%)
HKD 4.06
(-0.49%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 6.65 Billion CNY | -2.77% |
| 2022 | 6.84 Billion CNY | 45.38% |
| 2021 | 4.7 Billion CNY | 48.59% |
| 2020 | 3.16 Billion CNY | 33.44% |
| 2019 | 2.37 Billion CNY | 55.19% |
| 2018 | 1.52 Billion CNY | 78.47% |
| 2017 | 857.27 Million CNY | 46.58% |
| 2016 | 584.83 Million CNY | 2.57% |
| 2015 | 570.16 Million CNY | -35.47% |
| 2014 | 883.6 Million CNY | 30.43% |
| 2013 | 677.46 Million CNY | 23.44% |
| 2012 | 548.82 Million CNY | 20.23% |
| 2011 | 456.49 Million CNY | -61.65% |
| 2010 | 1.19 Billion CNY | 105.49% |
| 2009 | 579.26 Million CNY | 123.31% |
| 2008 | 259.4 Million CNY | 196.06% |
| 2007 | 87.61 Million CNY | -8.72% |
| 2006 | 95.98 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 6.02 Billion CNY | -5.04% |
| 2024 Q1 | 6.34 Billion CNY | -4.7% |
| 2023 Q4 | 6.65 Billion CNY | -14.75% |
| 2023 FY | 6.65 Billion CNY | -2.77% |
| 2023 Q1 | 7.52 Billion CNY | 9.94% |
| 2023 Q2 | 8.16 Billion CNY | 8.54% |
| 2023 Q3 | 7.8 Billion CNY | -4.42% |
| 2022 Q3 | 6.5 Billion CNY | 13.09% |
| 2022 FY | 6.84 Billion CNY | 45.38% |
| 2022 Q1 | 5.06 Billion CNY | 7.58% |
| 2022 Q4 | 6.84 Billion CNY | 5.24% |
| 2022 Q2 | 5.75 Billion CNY | 13.55% |
| 2021 Q3 | 4.15 Billion CNY | 15.13% |
| 2021 Q1 | 3.44 Billion CNY | 8.59% |
| 2021 Q2 | 3.61 Billion CNY | 5.0% |
| 2021 FY | 4.7 Billion CNY | 48.59% |
| 2021 Q4 | 4.7 Billion CNY | 13.19% |
| 2020 FY | 3.16 Billion CNY | 33.44% |
| 2020 Q3 | 3.34 Billion CNY | 12.51% |
| 2020 Q4 | 3.16 Billion CNY | -5.27% |
| 2020 Q2 | 2.97 Billion CNY | 11.83% |
| 2020 Q1 | 2.65 Billion CNY | 11.95% |
| 2019 Q3 | 2.06 Billion CNY | 13.08% |
| 2019 Q4 | 2.37 Billion CNY | 14.87% |
| 2019 Q1 | 1.58 Billion CNY | 3.52% |
| 2019 Q2 | 1.82 Billion CNY | 15.41% |
| 2019 FY | 2.37 Billion CNY | 55.19% |
| 2018 Q4 | 1.52 Billion CNY | -3.38% |
| 2018 FY | 1.52 Billion CNY | 78.47% |
| 2018 Q3 | 1.58 Billion CNY | 89.24% |
| 2018 Q2 | 836.71 Million CNY | -9.07% |
| 2018 Q1 | 920.15 Million CNY | 7.34% |
| 2017 Q4 | 857.27 Million CNY | -8.4% |
| 2017 FY | 857.27 Million CNY | 46.58% |
| 2017 Q3 | 935.91 Million CNY | 26.82% |
| 2017 Q2 | 737.97 Million CNY | 10.69% |
| 2017 Q1 | 666.72 Million CNY | 14.0% |
| 2016 Q1 | 573.29 Million CNY | 0.55% |
| 2016 FY | 584.83 Million CNY | 2.57% |
| 2016 Q3 | 594.31 Million CNY | -2.77% |
| 2016 Q4 | 584.83 Million CNY | -1.6% |
| 2016 Q2 | 611.26 Million CNY | 6.62% |
| 2015 Q2 | 563.44 Million CNY | -14.83% |
| 2015 Q1 | 661.53 Million CNY | -25.13% |
| 2015 Q3 | 589.31 Million CNY | 4.59% |
| 2015 FY | 570.16 Million CNY | -35.47% |
| 2015 Q4 | 570.16 Million CNY | -3.25% |
| 2014 Q3 | 949.35 Million CNY | -8.16% |
| 2014 Q2 | 1.03 Billion CNY | 89.17% |
| 2014 Q1 | 546.42 Million CNY | -19.34% |
| 2014 Q4 | 883.6 Million CNY | -6.93% |
| 2014 FY | 883.6 Million CNY | 30.43% |
| 2013 Q3 | 608.65 Million CNY | -1.06% |
| 2013 Q4 | 677.46 Million CNY | 11.31% |
| 2013 Q1 | 561.82 Million CNY | 2.37% |
| 2013 FY | 677.46 Million CNY | 23.44% |
| 2013 Q2 | 615.18 Million CNY | 9.5% |
| 2012 FY | 548.82 Million CNY | 20.23% |
| 2012 Q4 | 548.82 Million CNY | 46.7% |
| 2012 Q3 | 374.09 Million CNY | 10.11% |
| 2012 Q2 | 339.73 Million CNY | 29.05% |
| 2012 Q1 | 263.26 Million CNY | -42.33% |
| 2011 FY | 456.49 Million CNY | -61.65% |
| 2011 Q2 | 482.72 Million CNY | -52.87% |
| 2011 Q3 | 375.81 Million CNY | -22.15% |
| 2011 Q4 | 456.49 Million CNY | 21.47% |
| 2011 Q1 | 1.02 Billion CNY | -13.95% |
| 2010 Q1 | 819.35 Million CNY | 41.45% |
| 2010 FY | 1.19 Billion CNY | 105.49% |
| 2010 Q4 | 1.19 Billion CNY | -9.52% |
| 2010 Q3 | 1.31 Billion CNY | 3.39% |
| 2010 Q2 | 1.27 Billion CNY | 55.31% |
| 2009 FY | 579.26 Million CNY | 123.31% |
| 2009 Q2 | 235.05 Million CNY | 0.0% |
| 2009 Q4 | 579.26 Million CNY | 0.0% |
| 2008 FY | 259.4 Million CNY | 196.06% |
| 2007 FY | 87.61 Million CNY | -8.72% |
| 2006 FY | 95.98 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | -54455.311% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | -379.179% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | -91491.339% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | -2059.738% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | -1441.067% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | -2132.129% |
| Essex Bio-Technology Limited | 62.82 Million HKD | -10492.021% |
| Tongfang Kontafarma Holdings Limited | 98.26 Million HKD | -6671.529% |
| PuraPharm Corporation Limited | 175.59 Million HKD | -3689.422% |
| SSY Group Limited | 1.08 Billion HKD | -512.558% |
| JBM (Healthcare) Limited | 91.58 Million HKD | -7165.503% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | -1993.429% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 81.04% |